M
Metaphore Biotechnologies
Biotech platform leveraging machine learning and molecular mimicry to create transformative therapeutics
About Metaphore Biotechnologies
Metaphore Biotechnologies is a biotech startup that operates in the field of therapeutic drug discovery and development. The company's primary focus is on the creation of new molecules for therapeutic benefit, using a unique approach called biomimicry. Biomimicry is the design and production of materials, structures, and systems that are modeled on biological entities and processes. In simple terms, Metaphore Biotechnologies is taking inspiration from nature to engineer therapeutics that can trigger the ideal response in the human body.
The company's proprietary platform, MIMiC, uses machine learning and molecular mimicry to create these transformative therapeutics. This platform allows the company to make previously inaccessible targets accessible in their mimic form, which could potentially lead to breakthroughs in the treatment of various diseases.
Metaphore Biotechnologies serves clients in the pharmaceutical and healthcare industries, including research institutions and drug development companies. The company's business model revolves around the use of its MIMiC platform to design and develop new therapeutic molecules. It makes money by licensing its technology to other companies, collaborating with other firms on drug development projects, and potentially, selling its own developed drugs in the future.
In summary, Metaphore Biotechnologies is a pioneering biotech startup that uses machine learning and biomimicry to design new molecules for therapeutic benefit, serving clients in the pharmaceutical and healthcare industries.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2021
- Headquarters
- Cambridge, United States
- Employees
- 51
- Open positions
- 3
- Dealroom signal
- 65.1/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Woman Founder, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VC✓Equity / VC | Aug 2026 | $0 | — | Lotte | ↗ |
| LATE VC✓Equity / VC | Apr 2026 | $0 | — | Toho Holdings (Japan) | ↗ |
Growth signals
Latest recorded traffic for Metaphore Biotechnologies is 3.9K monthly website visits, up 18.2% over the last three months. Metaphore Biotechnologies's team declined 8.9% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later3 investors entered at this stage
Flagship Pioneering
Toho Holdings (Japan)
Lotte
Other known investors1 additional known investor
UNM Rainforest Innovations
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Metaphore Biotechnologies on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Metaphore Biotechnologies’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







